Company	Compound	Phase	Indication & Inclusion Criteria	Locations	Clinical Trial
Exon Skipping					
Entrada	ELEVATE-44-201	Phase I & II	Duchenne Muscular Dystrophy 4 years to 20 years Ambulatory Amenable to exon 44 skipping	BEL, ITA, ESP, GBR	NCT07037862 (ELEVATE-44)
Entrada	ELEVATE-45-201	Phase I & II	Duchenne Muscular Dystrophy 4 years to 20 years Ambulatory Amenable to exon 45 skipping	BEL, ITA, NLD, ESP, GBR	NCT07038824 (ELEVATE-45)
Gene Therapy					
Precision BioSciences	PBGENE-DMD	Phase I & IIa	Duchenne Muscular Dystrophy 2 Years to 7 Years Ambulatory Mutation between Exons 45-55	USA (AR, MO)	NCT07429240 (FUNCTION-DMD)
Solid Biosciences	SGT-003	Phase I & II	Duchenne Muscular Dystrophy 0 Year to 17 Years Ambulatory and/or non-ambulatory Mutations Not within Exons 1-11, 42-45, 57-69	USA (AR, CA, GA, IL, MO, OH, OR, PA, VA, WA) CAN, ITA, GBR	NCT06138639 (INSPIRE DUCHENNE)
Sarepta	SRP-9001	Phase I	Duchenne Muscular Dystrophy 2 Years and older Cohort 8: Non-ambulatory	USA (AR, CA, FL, IL, MO, NC, TX, VA)	NCT04626674 (ENDEAVOR)
Sarepta	Gene Therapy long-term follow-up	Phase IV	Duchenne Muscular Dystrophy 4 Years and older Patients have been prescribed delandistrogene moxeparvovec Mutations Not within Exons 8-9	USA (AL, AR, CA, CO, CT, DC, FL, IL, IN, KS, KY, MA, MI, NM, NY, NC, OH, OR, PA, TN, TX, VA, WA, WI)	NCT06270719 (ENDURE)
Anti-inflammatory					
Nationwide Children's Hospital Children's Hospital of Chicago Children's Hospital Medical Center, Cincinnati	Prednisolone	Phase IV	Duchenne Muscular Dystrophy 1 Month to 30 Months	USA (IL, OH, TX)	NCT05412394

Others					
Italfarmaco	Givinostat	Phase III	Duchenne Muscular Dystrophy 9 Years to 17 years Non-ambulatory	BEL, CAN, FRA, DEU, ITA, NLD, ESP	NCT05933057 (ULYSSES)
Sardocor Corp/Medera	SRD-001 (AAV1/SERCA2a)	Phase Ib	Duchenne Muscular Dystrophy 18 Years and older	USA (KS, OH)	NCT06224660 (MUSIC-DMD)